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Abstract 
Introduction: Nanocarriers have emerged as a powerful alternative for cancer therapy. 
Indeed, they are promising candidates to tackle the acquired resistance of surviving cells 
against antiproliferative drugs – the so-called multidrug resistance (MDR) phenomenon 
– which has arisen as one of the major clinical issues of chemotherapy. Among 
nanocarriers, this review focuses on the recent approaches based on tailored mesoporous 
silica nanoparticles (MSNs) that could overcome this problem. 
Areas covered: Herein we summarize the current efforts developed to provide MSN-
based nanosystems of enhanced dual therapeutic action against diseased cells. This can 
be accomplished by three main approaches: i) increasing nanosystems’ killing 
capability towards particular cells by enhancing both recognition and specificity; ii) 
increasing the apoptotic effect throughout co-delivery of several drugs; or iii) 
combining drug delivery with apoptosis induced by physical methods. 
Expert Opinion: The development of multifunctional nanosystems able to exert the 
optimal therapeutic action through the minimal administration constitutes a major 
challenge in nanomedicine. Recent developments in advanced MSN-based platforms for 
drug delivery represent promising avenues in the management of MDR associated with 
cancer therapy. All strategies discussed in this manuscript demonstrate improvements 
against difficult-to-treat tumors. 
 
Keywords: cancer treatment, multidrug resistance, co-delivery, combination therapy, 
dual targeting, mesoporous silica nanoparticles. 
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Article highlights. 
• Cancer cells tend to develop survival mechanisms against the usual 
chemotherapeutic employed for their treatment. Among known factors of 
enhanced survival there could be found antiapoptotic routes or drug efflux 
pumps that create this resistance to antitumor drugs. 
• Nanocarriers and among them mesoporous silica nanoparticles are able to 
preferentially accumulate within the tumor mass and efficiently deliver 
toxic payloads; however, the delivery of one type of therapeutic compound 
usually does not solve the problem of acquired resistance, like raw drug 
administration.  In spite of guidance has improved the selectivity and 
efficiency of the treatment towards diseased cells, there is still an issue 
when multidrug resistance appears. 
• One recent attractive strategy to overcome the high survival ratio of 
multidrug resistance cancers consists in specifically targeting a concrete 
group of (diseased) cells by increasing the preferential uptake of 
nanotherapeutic and therefore reducing the overall dosage needed for the 
treatment. 
• Another interesting approach is based on the maximization of the killing 
potential of carriers by including combinations of substances as cargoes 
able to exert simultaneous or synergistic action on more than one critical 
metabolic pathway. 
• Furthermore a highly promising alternative to increase cell death could be 
also generated by dual combination of antiproliferative drugs with physical 
stimuli able to trigger additional apoptotic responses. 
This box summarizes key points contained in the article 
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1. Introduction 
Currently, one of the pivotal pillars of cancer therapy is based on the use of chemical 
compounds to induce cellular death. However, the systemic administration of cytotoxic 
drugs enhances cell death in both tumor and healthy tissues. Unluckily this lack of 
selectivity usually provokes severe side effects in the patient that reduce its potential 
applicability. To avoid this limitation, the biomedical scientific community has done 
many efforts to increase the therapeutic profiles of those cytotoxic drugs. One of the 
most promising approaches is based on the development of nanocarriers to selectively 
reach tumor areas and release on-site cytotoxic payloads [1,2]. Unfortunately, the 
extensive use of chemotherapy has also leaded to additional problems that remain 
unsolved. One of the most important is the acquired resistance of surviving cells against 
the employed drugs, which drastically reduces the efficacy of such chemotherapeutics 
for future treatments. This phenomenon is called multidrug resistance (MDR) [3].  
Among all reported nanocarriers, mesoporous silica nanoparticles (MSNs) are of high 
interest as they show unique properties such as large surface areas (700-1000 m2 g-1) 
and pore volumes (0.6-1 cm3 g-1), which offer high loading capacity, tunable sizes (50-
300 nm), morphology and pore diameters (2-6 nm), robustness and easy 
functionalization [4-13]. These characteristics provide excellent opportunities to host 
different therapeutic agents. MSNs, as many other nanosystems, also exhibit good 
biocompatibility [14]. However the use of MSNs is still far from the application in 
clinical trials because of not enough evidences of safety and therapeutic efficacy of 
these nanosystems [12]. 
This review overviews the scientific efforts developed up to date to provide MSNs-
based nanosystems of enhanced dual therapeutic actions against MDR in cancer cells 
[15-19]. This challenging goal may be tackled through three main approaches: i) 
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improving the nanosystems’ targeting towards diseased cells by enhancing both 
recognition and specificity; ii) enhancing the nanosystems’ apoptotic effect throughout 
the co-delivery of several therapeutic agents; and iii) improving killing capability by 
combination of drug delivery with apoptosis induced by physical methods, such as 
photodynamic therapy, photothermal therapy or magnetic hyperthermia.  
 
2. Enhancing the recognition by dual targeting 
Most of reported applications of nanocarriers, including those approved as 
pharmaceuticals, are mainly based on unspecific passive accumulation within the tumor 
mass due to the well-known enhanced permeation and retention (EPR) effect [20, 21]. 
Recent investigations have demonstrated that the selectivity can be increased by active 
targeting, i.e. surface decoration of nanocarrier with targeting ligands that are able to 
promote internalization through recognition of diseased cells overexpressing specific 
receptors. Thus, active targeting provides better therapeutic profiles as nanocarriers are 
preferentially accumulated by target cells. Nevertheless, the uptake of nanocarriers by 
other non-diseased cells in which the implicated receptors are also present is still a 
challenging problem. In an effort to overcome these issues, some advanced targeting 
approaches have been developed [22, 23]. In the next sections we will focus on MSNs 
as versatile and modular systems, albeit some of the described strategies are also 
feasible for other nanocarriers [24]. Some relevant examples of liposomal and 
polymeric formulations can be found by the reader in the Expert Opinion section. 
Unspecific cellular recognition may produce important and undesired side effects, 
similar to those generated by conventional chemotherapy. Firstly, a poor specificity in 
cellular recognition may mismatch the targeting destination from the therapeutic area, 
thus lowering the treatment efficiency. And secondly, but also important, is that non- or 
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poorly targeted systems might lead in long-term, low-dose exposure of diseased cells to 
cytotoxic drugs, which could increase the chances of developing MDR by those tumors. 
This can take place either by evolution through down-regulation of implicated receptors, 
or by overexpression of efflux pumps such as P-Glycoprotein (Pgp) [25-27], and/or 
other ATP-Binding Cassettes (ABC) transporters responsible of xenobiotics draining 
out of the cell [28, 29]. 
In this section, some current strategies aimed at improving the efficiency of MSNs-
based nanomedicines for cancer therapy will be overviewed, focusing on either 
membrane-nuclear targeting or vascular-cellular targeting. Special emphasis will be 
devoted to the efforts accomplished so far to increase the selectivity of nanocarriers to 
deal with MDR tumor cells. 
2.1 . Membrane-Nuclear targeting 
As previously stated, one of the main challenges in the application of nanomedicine to 
cancer treatment is the specific delivery of nanocarriers to tumors. In this sense, the use 
of highly expensive but specific antibodies would partially solve this problem, as they 
could specifically recognize diseased cells, although they may originate immunogenic 
responses in the organism. They also offer important advantages since antibodies are the 
most specific targeting moieties known up to date. Thus an antibody targeted carrier 
would be expected to mainly interact with the target cells and therefore minimize the 
misplaced release of chemotherapeutics. However, many of the known antibodies target 
alike diseased and healthy cells that express the complementary antigen, which could 
discard them for cell targeted cancer therapy. In addition the use of antibodies is 
problematic as its grafting onto nanoparticles may require harsh conditions which may 
lead to their denaturalization. For this reason, new vectorization strategies are worth of 
exploring, since efficient deliveries of chemotherapeutic could significantly reduce the 
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side effects associated to the inherent drug toxicity and thus the development of drug 
resistance.  
In one the first reported examples, Pan et al. designed doxorubicin (DOX) loaded MSNs 
decorated with two different bioactive peptides on the surface; one responsible of 
cellular membrane recognition and another able to actively deliver the carrier to the 
nucleus (Figure 1.i) [30]. The chosen c(RGDyC) peptide interacted with the αvβ3-
integrin present on cellular membranes of HeLa cellular line, while the transactivator of 
transcription (TAT) peptide from human immunodeficiency virus (HIV) facilitated the 
penetration to the nucleus of the cell [31-33]. Their results evidenced a preferential 
accumulation of dual-targeted MSNs compared with non-targeted or single-TAT 
targeted nanoparticles (Entry 1, Table 1). 
In a similar way, Xiong et al. designed a double-targeted system based on two small 
bioactive molecules: folic acid (FA), able to interact with the folate receptors (a-FR) 
overexpressed on HeLa cell membranes, and Dexamethasone (DEX) which interacts 
with the nuclear glucocorticoid receptors able to induce nuclear translocation [34]. The 
use of DEX decorated nanoparticles showed a 5-fold increase in nuclear location as 
confirmed by flow cytometry analyses (Entry 2, Table 1).  
2.2 . Vascular-Cellular targeting 
It is known that tumor growth clearly depends on supplies received, so usually the result 
is the development of highly vascularized areas induced by angiogenic substances 
produced by those tumor cells. Thus antiangiogenesis became an interesting approach to 
the increase of therapeutic profile of nanomedicines as the targeting of tumor new-
forming vessels that could locally inhibit tumor growth [35-37]. Although this may 
induce tumor invasion and metastasis due to nutrient outage, a proper combination with 
cellular proapoptotic substances could effectively decrease its aggressiveness.  
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Some combinations of angiogenic therapy together with strategies to enhance cellular 
uptake have been reported. The results indicate that the overall accumulation of 
cytotoxic drugs within the tumor is improved, which increases the efficiency of the 
treatment. In a recent paper by Qiao et al. hollow MSNs (HMSNs) were functionalized 
with a single heptapeptide (tLyp-1) to target simultaneously two proteins within the 
Neurophilin family (NRP1 involved in angiogenesis and NRP2 in lymphangiogenesis) 
to enhance penetration into tumor parenchyma and arrest tumor development (Entry 3, 
Table 1) [38].  
 
3. Enhancing the cell death effect by combination therapy 
3.1. Dual delivery of cytotoxic drugs and small interfering RNAs (siRNAs) 
As previously remarked, the development of strategies to overcome MDR tumors would 
constitute a great milestone in cancer therapy [39]. Although some advances have been 
achieved to circumvent this issue, their immediate application still remains unclear.  
Usually MDR defines an ability of cancerous cells to become resistant to usual 
chemotherapeutics, which could be due two independent processes, namely pump and 
non-pump resistance. The pump resistance mechanism is originated by overexpression 
of several ATP-dependent membrane proteins, such as Pgp, [25, 26, 40] or other 
proteins responsible of active drug efflux from the cell. Thereby this continuous drug 
expelling reduces the overall amount of drug within the cell, thus decreasing its 
therapeutic efficacy. The Pgp is usually highly expressed in difficult-to-treat cancers 
such as stomach, breast and pancreas carcinomas; unfortunately it is also quite common 
in other metastatic tumors, and when highly expressed, it induces drug resistance 
through drug drainage efflux out of the cell. The non-pump resistance mechanisms 
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induce the activation of antiapoptotic defense usually mediated by antiapoptotic 
proteins such as Bcl family from which the most representative is Bcl-2 [41, 42] or 
Heat-Shock proteins (HSP) [43], whose overexpression prevents cellular death.  
As conventional chemotherapy usually activates both resistance processes, it would be 
necessary to inhibit those mechanisms to fight against MDR. However the current state 
of the art is mainly based in the disruption of one resistance paths, although promising 
results are obtained with the new generation targeted devices. 
Small interfering RNAs or silencing RNAs (siRNAs) are a kind of nucleic acids able to 
interfere with the normal gene expression of mammalian cells by competing with 
messenger RNAs (mRNAs). This is originated because siRNA are able to potently, 
persistently and specifically disrupt the normal effect of mRNAs that encodes drug-
resistance related proteins, thus increasing the efficacy of the drug-based treatment. 
MSNs based nanoparticles are of special interest because they can deliver cytotoxic and 
siRNA species simultaneously more efficiently than other nanosystem; and therefore 
increase the therapeutic profile by maximizing the concentration of chemotherapeutic 
while silencing the effect of proteins responsible of drug resistance [44,45]. 
For this strategy, it is important to note that the anchoring of siRNAs to the nanocarrier 
must be reversible as its way of action requires a final detachment of the nucleic acid to 
perform its therapeutic effect (Figure 1. ii). In this sense, MSNs are of great interest 
because their surface charge can be easily tailored to undergo electrostatic interaction 
with nucleic acids, oppositely to other nanoplatforms that require a complete redesign or 
specific synthesis to switch the superficial charge. Nevertheless there are many different 
examples on the literature where non-MSNs based nanoplatforms are also successfully 
employed. For a recent review on this topic please check reference [46].  
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In the first reported example on MSNs, Chen et al. functionalized the negatively 
charged outermost surface of DOX-loaded MSNs with positively charged generation 
2(G2) amine terminated polyamidoamindoamine (PAMAM) dendrimer via electrostatic 
attractive interactions that disappear under acidic lisosomal pH. The resulting cationic 
system was then suitable for the incorporation of the anionic siRNA effective against 
mRNA encoding Bcl-2 antiapoptotic protein [47]. Authors found that their complex 
increased cellular death in MDR A2780/AD human ovarian cancer cells, with an 
enhanced apoptotic effect 132 times greater than those of free DOX due to the 
suppression of Bcl-2 non-pump resistance. Moreover, the data demonstrated that DOX 
was mainly localized on the perinuclear region, what seemed to indicate an effective 
bypass of pump mediated resistance (Entry 1, Table 2).  A similar strategy was 
employed by the group of Zhao et al., who used DOX-loaded HMSN in which the role 
of polycationic linking material was played by a polyethyleneimine (PEI) polymer [48]. 
In this work the authors also included FA as targeting moiety. The evaluation against 
positive (HeLa) and negative (MCF-7) -FR breast cancer cells showed a clear 
internalization preference by the HeLa cell line. Subsequently, the down expression of 
Bcl-2 significantly reduced the viability of HeLa compared to that of MCF-7 cells 
(Entry 2, Table 2).  
A similar design has also been reported for the delivery of Pgp siRNA and DOX in 
several breast cancer cell lines by Meng et al. [49, 50]. As Pgp is one of the major 
pathways in drug resistance, the silencing of this efflux would increase the efficacy of 
the employed cytotoxic drug. In these works the authors chose phosphonate coated 
MSNs to guarantee high dispersability and biosafety. These nanosystems were able to 
electrostatically bind PEI polymer for further complexation of the siRNA, which exhibit 
an acidic dependent release. The treatment of DOX-resistant KB-V1 breast carcinoma 
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cells with the DOX-siRNA system resets the drug concentration values to those showed 
by the sensitive cells. In the most recent article the authors evaluated the behavior of 
different reported siRNA such as pump dependent (Pgp, MRP1 and ABCG2) and non-
pump dependent (Bcl-2, cMyc and PXR) [50]. From all tested cases authors found 
DOX- Pgp siRNA as the best combination for drug resistance reversion (Entries 3 and 
4, Table 2). 
Apart from the examples involving Bcl-2 and Pgp siRNAs, there also has been reported 
reversal resistance employing the micro RNA 221 (miR221), which is involved in 
several pathways such as angiogenesis or cell migration. Neuronal cancers as glioma are 
usually treated with a DNA alkylating agent such as temozolomide (TMZ) but its 
effectiveness is sometimes comprised by drug resistance. However, the combination of 
anti-miR221 with TMZ has proven to reverse glioma resistances according to the results 
reported by De Cola’s group (Entry 5, Table 2) [51]. Like in previous examples the 
siRNA-MSNs binding relies on electrostatic interactions, excepting that in this case the 
negatively charged silica particle binds a peptide-nucleic acid conjugate in which a 
peptidic section bears the positive charge responsible for electrostatic interaction. In 
vitro studies with this dual system show an important synergistic action of resistance 
reversion in T98G glioma cells not reached with each therapeutic alone.  
Another interesting approach is the co-delivery of a chemotherapeutic drug in 
combination with an angiogenesis down regulation RNA [35]. Such system, reported by 
Yin et al. combined the apoptotic effect of the drug with a nutrient outage to the tumor 
[52]. In this case the authors evolved the system with TAT cell penetrating peptide to 
increase the effect of the chemotherapeutic while building an on demand pH sensitive 
drug-releasing mechanism. The evaluation of this system on human hepatocarcinoma 
provided an additional advantage, as no guidance was required as liver spontaneously 
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accumulates most of xenobiotics. For the conjugation of both DOX and vascular 
endothelial growth factor (VEGF) siRNA the authors designed a multilayer system 
based on anionic and cationic layers able to sequentially disintegrate. The system 
releases stepwise the siRNA in the cytosol and the cytotoxic DOX in the perinuclear 
area due to the nuclear targeting of TAT peptide (Entry 6, Table 2) [31, 32]. The 
potential therapeutic effect of anti VEFG siRNAs containing nanomedicines was also 
confirmed by Chen et al. [53]. Thus magnetic MSNs were functionalized with 
Vasohibin-2 silencing RNA and the KALA fusogenic peptide, responsible of facilitating 
internalization in the outer region. Although authors did not use a conventional 
chemotherapeutic drug for apoptosis induction, the combined action of siRNA and the 
fusogenic peptide KALA proved to be effective in the in vivo treatment of ovarian 
adenocarcinoma tumors. Their system showed a 6-fold inhibition on tumor growth, 
compared with normal tumor progression. Unlike the previous combinations, only for 
therapeutic purposes, this system allows the diagnosis of tumor evolution by magnetic 
resonance imaging (Entry 7, Table 2). 
3.2. Multiple cytotoxic drugs delivery 
In the fight against tumor MDR, the combination of chemotherapeutic drugs is a 
promising strategy as the co-administration of more than one chemotherapeutic may 
hamper the cellular adaptation [54]. In fact this is the logical evolution of current 
therapies, which are based on the sequential administration of different drug cycles (or 
combined therapies) to attack the tumor on several fronts. A promising approach for 
enhancing cell sensitivity against chemotherapeutic compounds could be the delivery of 
hybrid drugs [55, 56], i.e. those combinations of single independent pharmacophores in 
a single molecule. Although this strategy could pave the way to new generation drugs 
based on simultaneous delivery or dual-actions, this could not be suitable for all 
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purposes. Some common issues for hybrid design are, firstly the own nature of drugs 
that could not allow conjugation without compromising their activity; secondly, a 
misplacement of pharmacophore destination mainly when both components act on 
different places; and thirdly, a poor pharmacokinetic/dynamic profile of hybrids 
compared to its individual components. Thus, the development of nanosized based 
carriers with its inherent drawbacks could be used to deliver combinations of discrete 
drugs and contribute to the improvement of therapy against MDR tumors by 
complementing the pharmacological profile of those hybrid drugs with a different way 
of delivery. 
The role of MSNs based nanomedicines against cancer promising as they are known to 
preserve the loaded compounds from external degradation and, if properly 
functionalized, also prevent those compounds from premature clearance or allowing 
programmed delivery. However, when compared to other systems such as polymeric 
nanoparticles or liposomes, the co-loading of several guests molecules into MSNs is 
complex, as it depends on many parameters such as the different solubility of guest 
molecules in the loading solvent, the different diffusion rates throughout the pores, the 
strength of interaction between loaded molecules and silica or the non-discardable 
retention value on the outer organic layer present in many nanodevices, among others. 
Oppositely, the preparation of polymeric and liposomal formulations with two or more 
loaded compounds is easier as usually loading and formation step occurs 
simultaneously. Regarding liposomal nanocarriers, their preparation is usually 
accomplished by adding the liposome components into a suspension of drug(s) under 
vigorous stirring. This forms the corresponding carriers containing the guest 
molecule(s) usually maintaining the same ratio employed previously; about polymeric 
carriers the common nanoprecipitation technique employs a solution of both drug(s) and 
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polymer which is carefully precipitated onto a second solvent, again under vigorous 
stirring, which produces the simultaneous precipitation of polymer and drug(s) that are 
maintained within the three-dimensional polymeric matrix. Because of this, it is easier 
to find more literature based on polymeric or liposomal carriers than available for 
MSNs. Within this line, different non-silica based nanocarriers loaded with different 
combinations of cytotoxic drugs, have been recently reviewed by Gadde [57]. 
However non-silica based systems also suffer important drawbacks that limit their use 
as nanotherapeutics. For example, there are post-functionalization difficulties for soft 
nanocarriers originated by their low stability when organic solvents are present or 
against many cycles of isolation. Thus, although multi-drug loading of MSNs is 
complex, they still present advantages against other common nanocarriers. Along this 
section there will be overviewed the efforts made in multidrug loading of MSNs 
towards MDR cancer therapy. As indicated, the loading and release of compounds from 
the MSNs’ mesopores is not an easy task, nevertheless an adequate delivery could be 
achieved when effective coatings are used. Their role is to hamper the undesired 
premature release of loaded compounds. This concept was first introduced to control the 
dual release of two molecules from MSNs [58]. As there will be discussed along the 
next paragraphs and summarized in Table 3, other strategies have been developed to 
attain this goal. 
Although most efforts have been focused on the development and use of coatings, there 
are also some examples in which one of the delivered drugs acts as pore blocker. Thus, 
Li and co-workers reported the one-pot construction of functional MSNs for the tumor 
acid-triggered synergistic chemotherapy of glioblastoma [59]. To this aim DOX was 
conjugated to MSNs through acid-cleavable hydrazone bonds and camptothecin (CPT) 
was loaded into the pores of MSNs. In the release studies there can be seen that at pH 
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6.5, similar to that in tumor tissues, and at pH 5.0 (similar to that of endo/lysosomes of 
cancer cells) a fast DOX release took place obeying the hydrolysis of hydrazone bonds 
kinetics. This allowed the release of CPT. The simultaneous delivery into tumor cells of 
CPT plus DOX provided good expectations in the treatment of glioblastoma (Entry 1, 
Table 3). In another work, Liu et al. reported the use different combinations of well-
known chemotherapeutics and profited of their different solubility and adhesion to 
develop a strategy for the sequential loading in which the latter acts also as capping 
moiety [60]. The strong electrostatic interaction exhibited by DOX-SiO2 pair was used 
to maintain the other hydrophobic drug within the pores. It is also noteworthy that DOX 
release is slower in the case of the MSNs containing both drugs, which is justified by 
unfavorable kinetics for alternating outflow. The therapeutic profile of the double 
loaded MSNs was studied against alveolar cancerous cells showing an enhanced 
apoptotic effect than the obtained for the single drug model (Entry 2, Table 3).  
Although the controlled multiple loading-release of two or more chemical entities 
within the channels of the MSNs is not simple, the ease of post-loading 
functionalization turn them into a valuable rigid and robust candidate for the 
construction of containment coatings able to avoid drug leakage. On the first reported 
MSNs-based co-delivery a model fluorophore was placed in the pores while a pH 
disintegrable cisplatin (CDDP) containing a polyelectrolyte multilayer was used as 
coating shell with both load and protective roles [61]. In this work Wan et al. employed 
alternating negative-positive polymers to coat the cationic amino functionalized MSNs, 
but adding Pt complexes in between layers to effectively trap them into the polymeric 
matrix. The polymeric shell so designed proved to be broken in acidic media because of 
the disappearance of the negative carboxylate groups. This produced the electrostatic 
interaction disappearance and the release amino containing CDDP complex (Entry 3, 
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Table 3). A similar strategy was employed by Li et al. for the encapsulation and 
delivery of CPT and DOX in HMSNs [62]. Their design was based on electrostatic 
adhesion of ZnO quantum dots (QD) to the carboxylate-functionalized surface of the 
silica nanoparticles. In this work the authors also performed sequential loading of 
cytotoxic drugs in which DOX was the latter incorporated compound. In vitro cellular 
assays with the material against A549 and MCF-7 cellular lines showed interesting 
enhanced apoptotic effect when using the QD-CPT-DOX system (Entry 4, Table 3). It is 
also remarkable that the QD-DOX combination performs significantly better than free 
DOX; this could be due to a delivery effect alone or to a combined effect of DOX with 
the possible toxicity of the QD employed.  
Another known approach for a controlled release is based on the MSNs coating with a 
lipid layer. These hybrid materials combine the loading capacity and robustness of silica 
with the outstanding protective effect of micelles. Along this line, Nel and coworkers 
employed lipid coated MSN loaded with Paclitaxel (PTX) and Gemcitabine (GEM), 
two first line chemicals for pancreatic cancer treatment, for its evaluation in mice [63]. 
The in vivo results with this material showed an increased therapeutic effect compared 
with the separate drugs, including commercial nanomedicines. In vivo assays indicated a 
slight tumor volume regression when treated with their double drug system oppositely 
to the tumor stasis obtained with the rest of single-drug chemotherapeutics (Entry 5, 
Table 3). 
As there will be reviewed below, the use of additional sensitizing agents in combination 
with anti-proliferative drugs could also exert reversal drug resistance. The incorporation 
of various hydrophobic compounds into the pores of MSNs could be also successfully 
achieved by performing the synthesis of MSNs with surfactant-stabilized 
chemotherapeutics. In most of reported literature on this topic, the therapeutic effect 
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usually relies in a single drug. However the presence of a surfactant has demonstrated to 
act as cellular sensitizer through destabilization of cellular membranes or by being the 
substrate for drug efflux pumps. In a pioneering work, Vivero-Escoto’s group used as 
prepared MSNs containing a non-toxic phosphonate surfactant, which were loaded with 
resveratrol (RVT) as hydrophobic model molecule [64]. The loading was achieved by 
soaking the surfactant containing MSNs into a concentrated solution of RVT, which 
allowed an effective loading within the surfactant. The in vitro evaluation against HeLa 
cell line showed a pH dependent release of RVT together with a slight decrease on the 
cellular viability (Entry 6, Table 3). Almost simultaneously, He et al. reported the use of 
an aqueous DOX stabilized with cetyltrimethylammonium bromide (CTAB) micelles 
for its use as mesopore template. The resulting DOX-CTAB loaded MSNs were tested 
in vitro against MCF-7 resistant and non-resistant cell lines [65]. In this case CTAB was 
chosen as surfactant as it provided the highest lethal effect on cells [66]. The 
combination of both drug and sensitizer provided better results in combination than 
independently, as demonstrated by cell viability studies (Entry 7, Table 3). 
The satisfactory results derived from the combination of cytotoxic plus drug efflux 
pump substrates encouraged other research groups to develop different systems to 
entrust both effects using lower-cost components than siRNAs. The reported example 
by Zhang et al. employed irinotecan (IRN) loaded MSNs coated with a Pluronic® (Basf 
Corporation) containing phospholipid shell [67]. The P123 block copolymer conjugated 
to the hybrid phospholipid was able to disrupt the drug efflux pump resistant route. 
Furthermore the lipid shell employed provided some additional features such as higher 
dipersability due to Pluronic® hydrophilic component and the controlled release 
behavior due to the pH-sensitive coating by the lipid layer; the pH-sensitivity and the 
effect of membrane-destabilizing agents were elegantly demonstrated in drug release 
D
ow
nl
oa
de
d 
by
 [B
ibl
iot
ec
a U
niv
ers
ida
d C
om
plu
ten
se
 de
 M
ad
rid
], 
[R
afa
el 
Ca
sti
llo
] a
t 0
6:2
8 1
2 J
uly
 20
16
 
18 
 
studies, which showed increased uptake for the lipid formulation with an expected 
increase in the amount of internalized IRN and reduction of viability on MCF-7 cellular 
line (Entry 8, Table 3). A similar research work by the group of Wang reported a similar 
device with DOX loaded MSN coated with a lipid shell [68]. The authors included a 
tocopherol-PEG hybrid inlaid within the lipid coating as substrate for the Pgp protein 
and a redox sensitive shell on reducible disulfide bridges between the MSN and the 
lipid molecules. The dual pH-redox combined release systems provided a stable and 
effective pore capping as seen on the nitrogen adsorption isotherms and measured pore 
diameters. The in vitro study with MCF-7 cell line showed an enhanced uptake and 
cellular death assumed by reversal drug resistance (Entry 9, Table 3). Along this line, Li 
et al in a recent work demonstrated that use of other drug combinations, such as DOX 
plus anti-angiogenic Combretastatin A4 (CA4), loaded into MSNs also provide an 
enhanced apoptotic effect and delay on tumor growth [69]. The system was further 
targeted with the RGD peptide as guidance moiety. The apoptotic effect in vitro showed 
similar values for both DOX and DOX+CA4 loaded nanoparticles, consequence of the 
low inherent toxicity of CA4 however in vivo data showed the clear inhibition of tumor 
growth, demonstrating the potential of  this strategy (Entry 10, Table 3). 
 
4. Combination with apoptosis induced by physical methods 
Another developing approach for the dual treatment of cancer is the combination of 
classic cytotoxic drugs with an additional effect, generated by exposure to a physical 
stimulus; either able to sensitize the cancerous tissue to the effect of chemotherapeutic 
or to induce an additional and independent apoptosis route. As previously discussed, 
combinations of cellular killing pathways provokes enhanced therapeutic profiles in 
drug resistant cancerous cells. Furthermore, the application of the apoptosis induced by 
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physical methods to MSNs based nanocarriers is highly interesting as the triggering of 
this apoptotic pathway would only occur in the areas where the nanocarrier is, thus 
minimizing undesired side effects. 
4.1. Photodynamic therapy 
Photodynamic therapy (PDT) is based on the use of a substance, a photosensitizer (PS), 
able to absorb concrete wavelengths of electromagnetic radiation. The generated excited 
state is able to transfer this energy to molecules containing oxygen atoms and produce 
the so-called reactive oxygen species (ROS). These high-energy compounds are 
potential cytotoxics as their high reactivity and low selectivity generate irreversible 
cellular damage, thus favoring cellular death (Figure 2.v) [70]. The use of PDT is 
improved for biomedical applications when two-photon absorption in the visible (Vis) 
or near infrared (NIR) regions is employed, since a deeper tissue penetration together 
with a reduction of the risks associated with ultraviolet (UV) light handling needed for 
single photon PDT is obtained [71].   
Although PDT based on mesoporous silica platforms is a quite exploited research field, 
the authors’ interests have been mainly focused in the development of new hybrids with 
different nature PS rather than in their combination with antiproliferative drugs. For 
instance, Gary-Bobo et al. used mannose targeted MSNs functionalized with a water-
soluble porphirin sulfonate PS and loaded with CPT [72]. As expected, the CPT exerted 
a cancerostatic action reducing the viability of all cellular lines tested to ca. 60%. 
Nonetheless, the combined effect with PDT dropped the survival of HCT116 and MDA-
MB-231 to ca. 20% while Capan-1 line showed complete cellular death, thus probing a 
synergistic effect (Entry 1, Table 4). 
In a similar approach reported by Yang et al. a porphyrin based PS (Chlorin e6) was 
introduced within the silica matrix by reaction with an alkoxysilane followed by co-
D
ow
nl
oa
de
d 
by
 [B
ibl
iot
ec
a U
niv
ers
ida
d C
om
plu
ten
se
 de
 M
ad
rid
], 
[R
afa
el 
Ca
sti
llo
] a
t 0
6:2
8 1
2 J
uly
 20
16
 
20 
 
condensation with the silica precursor. Then, the so obtained nanorods were loaded with 
DOX and evaluated against several cell lines [73]. The reported results showed a 
synergistic effect higher than the theoretical additive effect of both monotherapies, 
demonstrating again the potential of combined therapy (Entry 2, Table 4). A nice 
implementation of the system, done by Chen and coworkers, employed Zn-porphyrin 
PS as a pore blocker [74]. In their design, MSNs loaded with DOX were functionalized 
with double pH features able to respond to both extra- and intracellular acidic 
microenvironments. The pore capping unit, formed by the PS, the pH sensitive cis-
aconitic moiety and polyethyleneglycol (PEG), was electrostatically linked to histidine 
decorated MSN which gave an acidic cleavable bonding between both subunits. 
Unfortunately, no relevant studies regarding the therapeutic effect are provided in this 
work (Entry 3, Table 4). A recent work by Vivero-Escoto and Elnagheeb also 
demonstrated the potency of the combined chemophotodynamic therapy by reducing the 
survival of HeLa cells. For so, they employed MSNs loaded with a combination of a 
phthalocyanine as sensitizer and CDDP as chemotherapeutic [75]. In this work, the 
authors provided clear data proving that combination therapy is much more effective 
than separated or simultaneously applied monotherapies (Entry 4, Table 4).  
Apart from the organic-based sensitizers, there is also an interesting approach based on 
radiation upconversion luminiscence implemented for drug delivery reported by Liu and 
coworkers. In this strategy they use lanthanide-doped particles for transformation of the 
incident NIR light into high-energy UV photons. The group reported two different non-
MSNs based models in which the UV emission performs the release of a Pt prodrug 
linked through an UV sensitive bond [76] or generation of ROS upon excitation of TiO2 
particles conveniently placed on the surface of their upconversion nanodevices [77]. 
Furthermore, the authors have employed the exceptional properties of light 
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upconversion to design a system in which the photoactive species (NaYF4:Yb3+/Er3+) 
are embedded in a mesoporous silica further coated with a pNIPAAm copolymer layer 
with pH- and thermoresponsive properties. In this last example they effectively 
confined DOX within the pores in which premature cargo release was avoided by the 
outer hydrogel layer [78]. Although the object of this article was more focused on the 
luminescent properties rather than the therapeutic aspect of combination of PDT with 
chemotherapy, the development of those kinds of platforms could enable multimodal 
therapeutics plus interesting bioimaging properties (Entry 5, Table 4). 
4.2. Photothermal therapy 
Unlike the PDT in which the energy from light radiation should be energetic enough to 
convert low reactive triplet oxygen molecule into the high reactive singlet oxygen one, 
photothermal therapy (PTT) is based in a different phenomenon. In this case the infrared 
radiation, highly related with the vibrational excitation of molecules, acts over the PS 
and, through thermal relaxation, induces local heating. As it is known, any increase of 
local temperature within the cell triggers either an apoptotic mechanism or, if more 
intense, the thermal degradation of the tissue. Thermal induced apoptosis is usually 
balanced by expression of heat-shock proteins and, as expected, the combination of both 
thermal plus chemical apoptotic pathways could be harnessed to increase the efficiency 
compared to analogous monotherapy treatments (Figure 2.vi). 
Along this section different materials showing photothermal effect will be reviewed, but 
in general PTT is usually based on plasmonic resonance for inorganic materials and 
extended conjugation for organic ones. The most recurrent material for photothermal 
treatments are gold nanoparticles (AuNPs), whose ease of functionalization and known 
plasmonic resonance turn them into a wide spread material. In the pioneer work by 
Chen and coworkers they employed Au nanorods (AuNRs) as core coated by a MSN 
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shell for the loading and delivery of DOX [79]. Their studies showed a typical pH 
dependent DOX release from the shell mesopores which was substantially increased 
when NIR lighting was applied. In vitro studies with A549 cell line showed an 
enhanced cellular death when both chemo- and thermal effects were combined. 
Furthermore, authors claimed that the punctual photothermal effect assisted the 
endosomal escape, thus allowing the loaded drug to better diffuse throughout the cell 
(Entry 6, Table 4). In another work, Shi’s group used anionic AuNRs electrostatically 
bound to a cationic Fe3O4@MSN nanoparticle for a similar purpose [80]. Although 
there is no data about combined therapy in vivo, the authors provided a nice chart 
relationship between induced heating and chemotherapy. They showed that below 39ºC 
and above 45ºC the main operating effects were cytotoxicity and hyperthermia 
respectively, while at 42ºC the combined effect was increased respect to the different 
independent therapies. However, the local release of DOX may still perform therapeutic 
action over the remaining cancerous mass, thus increasing the potentially of this therapy 
(Entry 7, Table 4). 
Although Au is one of the most readily available materials for the construction of 
hybrids with mesoporous silica matrices, there are other many chemical sensitizers 
different in nature able to perform this task. In an example reported by Huang and 
coworkers, a graphene sheet behaving as PS was coated with mesoporous silica and 
loaded with DOX (Entry 8, Table 4) [81]. Another organic specie reported to behave as 
PS is polypyrrole (PPY), as it bears an extended conjugation similar to that of graphene, 
although linear in this case. Zhang et al. employed polypyrrole-polyacrylic acid (PPY-
PAA) nanoparticles as growing seeds for MSNs construction, which were successfully 
loaded with DOX as cytotoxic [82]. The authors reported an enhanced apoptosis when 
compared with raw cytotoxic similar to those obtained with other reported systems but 
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with a clear advantage, the lower cost of PS in comparison to other reported systems 
(Entry 9, Table 4). In addition to the graphene and PPY sensitizers, the organic 
sensitizer cypate (CYP) has also been satisfactorily employed for the construction of 
DOX containing micelles with photothermal properties [83]. Besides Au, other 
inorganic species could also act as PS, such as CuS [84]. Thus, Lu et al. have efficiently 
employed core@shell CuS@MSN nanoparticles for the delivery of DOX for combined 
treatment of HeLa cell line with efficiencies comparable to those obtained with neat 
chemotherapeutic agent (Entry 10, Table 4) [85].  
Another relevant contribution to the state of the art in multi-therapeutic use of MSNs 
was reported by Zhang et al. In their model they used CuS embedded in a mesoporous 
silica matrix able to respond to NIR irradiation to achieve thermal excitation at 980 nm. 
The authors employed a mixture of Curcumin (CUR) and DOX which have 
demonstrated to perform a toxic synergistic action [86]. The system was designed by 
loading of CUR within the pores and functionalizing the outermost surface by 
anchoring a single strand DNA. This DNA was hybridized with the recognition aptamer 
AS1411, which was able to perform cellular recognition and internalization on MCF-7 
breast line. Additionally, the cytotoxic drug DOX was intercalated within the double 
strand DNA to complete the system and allow double thermal release of CUR and 
DOX. (Entry 11, Table 4) [87].   
Despite the existence of organic sensitizers, Au is by far the most reported one. A 
number of examples also describe systems able to perform additional diagnostic 
features that could be also employed for combined therapy. As an example, the design 
by Lv et al. includes an inner lanthanide oxide particle for providing luminescent 
properties to the system. In this case the photothermal property resides in Au25 clusters 
embedded together with DOX within the pores. The system is completed with a thermal 
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sensitive poly(N-isopropyl acrylamide)metacrylic acid (poly(NIPAm-MAA)) (Entry 12, 
Table 4) [88]. In another example, Zhang et al. [89] reported the use a pH sensitive 
imine bond to link DOX to the surface of AuNR@MSN which may be photothermically 
accelerated. Again, the obtained results are in concordance with the previous observed 
behavior of cumulative apoptotic effects (Entry 13, Table 4). 
Two very recent examples including in vivo experiments support the hypothesis of 
combined light-induced photochemotherapy as a potential improvement for future 
therapeutics. In one example by Zhang et al. an octopus-like, Janus type Au-MSN 
nanoparticle was used to achieve complete tumor remission of liver tumors on mice 
when applying both therapeutic effects together (Entry 14, Table 4) [90]. The second 
recent example, by Wang et al., employed the synergistic therapy for melanoma 
treatment using several sizes of rod-type Au@MSN@Au nanohybrids loaded with 
docetaxel (DTX) [91] (Entry 15, Table 4). Their studies showed too complete remission 
of tumor when using combination therapy. Although this is out of the scope of the 
current review, which is mainly focused on MSNs as delivery agents, the authors would 
like to let the readers know that there is an interesting review about effects of 
synergistic combination of gene and PTT [92]. 
4.3. Magnetic hyperthermia 
Another well-known effect for enabling the thermal-mediated apoptosis of tumor cells 
is magnetic induced hyperthermia, which is efficiently generated by stimulation of the 
sensitive material to alternating magnetic fields (AMF). Although the use of magnetic 
materials has become widely employed and extensively reviewed, there are scarcely 
studies regarding combined thermo and chemotherapy with mesoporous magnetic 
materials. Lu et al. reported the synthesis of HMSNs encapsulating iron oxide 
nanoparticles (IONPs), [93] which allowed the resulting nanocapsule acting as DOX 
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delivery system. In fact, the hollow interiors of HMSNs permitted hosting high 
chemotherapeutic amounts; for further details into the comparison of HSMSNs and 
MSNs please check references included in the review authored by Tang et al. [12] Upon 
exposure to an AMF, IONPs promoted DOX release and also elevated the temperature 
of the surrounding media to clinical hyperthermia levels (41-46 ºC). Tao and Zhu 
prepared magnetic MSNs (mMSNs) by encapsulating Fe3O4 nanoparticles in MSNs and 
DOX was used as anticancer drug to evaluate the drug delivery capability of those 
mMSNs [94]. DOX-loaded in mMSNs was released in the medium at pH 5.0, similar to 
that in the intracellular endo/lysosomes. In addition, mMSNs efficiently generated heat 
upon exposure to an AMF due to their superparamagnetic performance. The two 
systems described herein provide promising nanoplatforms for the combination of 
chemotherapy and hyperthermia for antitumor therapy. In case the reader wished to 
deep into this topic there are several interesting reviews available for further reading 
[95-98].  
4.4. Radiotherapy 
Besides chemotherapy and surgical removal of malignant mass, radiotherapy is also an 
important pillar of cancer treatment. It is based on the application of highly ionizing and 
penetrating radiation able to destroy the tumor tissue; although, again, there is a lack of 
selectivity between health and malignant tissues. Fortunately, the therapeutic radiation 
could be focused to reduce its effect on neighbor tissues, but the selective effect on 
cancer cells is still a chimera. Nonetheless, the development of nanotechnology could 
advance the future radiotherapies by basing them in the preferential accumulation 
within the solid tumor masses possessing EPR effect. 
Most reported radioactive nanodevices are designed for diagnosis purposes [99] and 
usually the amount of radioactive material is not enough to achieve a therapeutic action. 
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However the advance in synthetic procedures may provide in the near future nice 
platforms for nanotransported sources of radioactivity (64Cu, 131I, etc.) [100, 101] even 
on mesoporous materials [102] thus enabling the on-site application of radio and 
chemotherapies or even on-demand combinations.  
Shen et al. reported a MSN-based nanosystem for reversing MDR by synergetic 
chemoradiotherapy [103]. For this purpose MSNs were loaded with topotecan (TPT), a 
typical radiosensitizing drug, and the outermost surface of the nanoparticles was 
decorated with PEG to improve biocompatibility. MSNs performed the transport of TPT 
into MDR cells while passing the Pgp pumps, and chemodrug-sensitized radiation 
improvement was directly accomplished within the cells by high energy X-ray 
irradiation. This was in vitro demonstrated using MCF-7/ADR cells (adriamycin-
resistant breast cancer cells), which experienced and increase in necrosis/apoptosis 
enhanced by DNA damage. The same research group reported the synthesis of rattle 
structure upconversion core/mesoporous silica nanoteranostics functionalized with TAT 
ligand to efficiently target cell nucleus [104]. The radiosensitizing drug mitomycin C 
(MMC) was confined into the nanosystems to be delivered into the nucleus upon 
exposure to high energy X-ray irradiation. In vitro and in vivo assays demonstrated the 
enhanced treatment efficacy by the intranuclear radiosensitization than the extracellular 
and intracellular ones in killing cancer cells and inhibiting tumor growth. 
Very recently, Ma and co-workers reported a novel B2S3-based nanoparticle, which is a 
well-known candidate as radiosensitizer upon exposure to X-ray irradiation, coated with 
a mesoporous silica shell and loaded with DOX into the mesopores [105]. In vitro 
assays demonstrated that the nanosystems exhibited on demand pH DOX responsive 
release and improved the therapeutic effect against MDR cancer cells. Besides, in vitro 
and in vivo experiments evidenced that the nanoplatforms could notably increase the 
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interstitial 32P radionuclide radiotherapy in the solid tumor. These findings revealed this 
novel nanosystem as a promising alternative for the synergistic combination of 
chemointerstitial radiotherapy. 
 
5. Conclusion 
Many of the recent biomedical research efforts are being dedicated to develop novel 
strategies able to overcome the current limitations of cancer therapy. Nanocarriers, 
namely MSNs, are outstanding and versatile candidates to achieve this goal. Advanced 
strategies have been designed to selectively targeting and killing cancer cells that have 
acquired resistance to usual chemotherapeutics. All the strategies reviewed in this 
manuscript clearly evidence that the main goal is to develop a library of 
nanotherapeutics that allow to increase cancer cell death while reducing the overall 
dosage needed for a successful treatment of difficult-to-treat tumors. Up to date only in 
vitro and preliminary in vivo assays have been performed, but much scientific effort 
must be still done before entering clinical trials. Some of the issues that must be 
addressed are determination of optimal size and shape for therapeutic application and 
clinical testing, establishment of dosage scales for murine and human experiments in 
order to minimize acute toxicity, determination of long-term toxicity and genotoxicity, 
studies about distribution in tissues and organs and an extensive study on MSNs’ 
metabolism and excretion. Additionally, precise preclinical host-guest loading-release 
studies must be accomplished to set standards in drug delivery and controlled release. 
But one of the most important issues may arise from the exceptional modularity of 
MSNs, because most of designs include fragments not fully evaluated components (the 
MSNs themselves are not fully clinically evaluated); such as set of linkers, building 
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blocks and even other particles that may give acute or chronic toxicities if systemic 
administration is systematically employed [106-112].  
 
6. Expert opinion 
Although MSNs have been widely exploited for the design of sophisticated nanodevices 
for antitumor therapy, they still remain in the forefront of scientific research, as MSNs 
allow unique modifications to include new features which otherwise could not be 
incorporated to classic treatments. One of the most recent strategies, focused on 
improving targeting, is the enhancement of cellular/tissue recognition through ligands 
selection to specifically match the receptors present in diseased cells.  
In the clinical practice, the combination of specific targeting and potent biological 
effects given by biomacromolecules (antibodies, aptamers, proteins, new generation 
peptides, etc.) with antitumor drugs has opened the way to more efficient cancer 
treatments; thus  improving the effect of classic chemotherapeutics, mainly for the 
treatment of relapsing and MDR tumors [113]. Nanocarriers, extraordinary platforms to 
combine in a single entity more than one therapeutic effect, are of special interest 
because they could be designed to deliver and then exert those effects simultaneously. 
Although this research field is still at its infancy and thus many efforts should still be 
made to achieve a real clinical application, some basic concepts for nanocarrier 
development are clear. 
The first examples of matching recognition were achieved via multi-ligand recognition 
onto diseased cells. Within this context, although contributions based on MSNs are not 
prolific, there are highly interesting approaches reported using different nanosystems. 
For example, RGD-based peptide combinations [26,114,115] (Entries 1 and 2, Table 5) 
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or dual-targeted formulations employing antibodies have been developed (Entries 8-10, 
Table 5) [116-118]. Albeit some antibody-based dual-targeting nanodevices involving 
angiogenesis (vascular-to-cellular) or membrane-to-nucleus are interesting, there are 
relevant issues that remain unsolved: the unknown immunogenic effect and an 
undemonstrated specificity towards the desired target cell. Another relevant approach, 
based on dual-aptamer recognition, has been also described for the specific recognition 
of different HER2 and MUC1 positive breast adenocarcinomas (Entry 3, Table 5) [119]. 
Perhaps the combination of low immunogenicity and high specificity of aptamers could 
give access to a new family of therapeutic nanocarriers with promising specificity 
towards particular tumor cell lines. Besides, aptamers offer several other advantages 
such as higher robustness than antibodies, which difficult manipulation and low stability 
could lead to false findings with devastating effects [120]. In any case, the possible 
combinations arisen from the use of several biomacromolecules as targeting moieties 
are practically unlimited. Then, for a reasonable development of targeted devices a 
concrete set of different specific-to-cell fragments would be highly appreciated by 
researchers in order to maximize the recognition process. 
Another crucial aspect of cancer therapy is the evolution of therapeutics against 
multidrug resistant cells. For so, the strategies regarding co-delivery and combination 
therapies show promising results, although still not fully developed. This issue remains 
unsolved in the clinical field but could be addressed by the delivery of two (or more) 
potent antiproliferative compounds; mainly when the combination simultaneously 
disrupts different replication routes. An overview of some clinical trials indicates that 
the combination of therapeutic compounds of different nature improves patient’s life 
expectancy, although sometimes it is hampered by the intensity of side-effects. 
Fortunately, the development of co-delivery strategies onto targeted-containing 
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nanocarriers could mitigate the therapy aggressiveness. However, more emphasis 
should be done on the study about the optimal drug ratio and drug combinations as 
employed in the clinical practice. This topic, which was smartly introduced by Johnson 
and coworkers, may establish relevant future guidelines for the development of more 
efficient nanomedicines [121]. To successfully adapt all these strategies to MSNs, they 
must be combined with different stimuli-responsive mechanisms, which fortunately are 
well developed [122]. 
An alternative and promising strategy is the simultaneous disruption of the replication 
route together with a crucial antiapoptotic pathway. Apart from the systems already 
reviewed along the manuscript, nanoplatforms are able to deliver interfering-based 
therapeutics together with cytotoxics (Entries 4 and 5, Table 5) [123, 124] have 
demonstrated that gene down regulation plus an apoptotic mechanism have potent 
antiproliferative effects. Furthermore, this approach enables an extraordinary potential 
therapeutic effect if multiple gene silencing are considered. So, the use of several 
nucleic acids able to disrupt several critical cellular pathways simultaneously [125] 
could boost the fight against cancer. Following this idea, the combination therapy of 
cytotoxic with down-expression of antiapoptotic related proteins could be an attractive 
approach. In the literature it has been reported that a single LPLTPLP peptide is able to 
play targeting and inhibition over heat-shock protein Hsp90 (Entry 6, Table 5) [53, 
126]. Also, the delivery of survivin siRNA shows nice results in combination with 
chemotherapeutic agents (Entry 7, Table 5) [127]. Nevertheless, all reported cases 
aligned onto this strategy have only preclinical results and then a knowledge on 
potential side-effects are required before new combinations are developed. 
It has been also reviewed that the combination of a single anti-proliferative compound 
with a sensitizer provides a substantial increase of the apoptotic effect of the chosen 
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drug. This strategy, although less efficient than the co-delivery of cytotoxics, could be 
interesting when the toxicity reached by the drug combination is not suitable for its use 
in systemic therapies. Furthermore, the presence of surfactants provides an additional 
advantage as the use of pore caps or coatings is usually not required. Following this idea 
Liu et al. have also reported that disruption of Pgp increases the therapeutic effect of 
antiproliferative drugs (Entry 11, Table 5) [128]. 
As a conclusion of the reviewed co-delivery approaches, it is possible to assume that 
most of the different nanosystems have increased the therapeutic profile with respect to 
the chosen cytotoxic drugs; which are now able to defeat and eradicate efficiently most 
of cancerous cell lines when tested in vitro. Unfortunately, although the results shown 
are promising, the reality is that most of these research do not have continuity in clinical 
studies; because of this, we strongly believe that future efforts should be addressed 
towards the evaluation of the most efficient combinations of basic systems more than to 
the development of more complex ones, with little or no preference for biogenic 
components which are always of preference.  
The combination of chemotherapy with apoptosis induced by physical methods is also 
an emergent discipline in the development of nanomedicines for future cancer therapies. 
The main advantages of this strategy are both low toxicity and ease to control intensity 
and location of stimuli, although the range of action might be restricted to superficial or 
easily reachable tissues. Despite the activation is innocuous for both PDT and PTT, 
there are several problems associated to the application of these combined therapies. 
These include the potential risk of long-term sensitivity of patients to remaining 
photoactive compounds within the organism, the development of resistance to PDT by 
the increment of antioxidant compounds, or long term toxicities to either PS or to the 
different employed components [71, 92]. Regarding photothermal ablation there is also 
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potential risk of inducing damages in neighbor healthy tissues. Nevertheless, the 
promising results obtained with light-responsive materials in combination with 
chemotherapy make relevant the development of new formulations for the 
implementation of current therapies, highlighting those in combination with those 
previously reviewed: targeting, gene knockdown and/or co-delivery. 
The development of nanotechnology may also provide many different systems with 
either enhanced selectivity or dual action modes. For example the combination of 
known ultrasound-responsive MSNs based drug delivery [129] with sonosensitive 
compounds [130], or radiochemotherapy would open up promising expectations in the 
development of new therapeutic possibilities for treatment of deep tumors in an easy 
fashion. 
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TABLES 
Table 1. Dual targeting strategies to design mesoporous silica nanoparticles-based 
nanosystems able to treat multidrug resistance (MDR) in cancer cells.  
(a) DEX: Dexamethasone 
(b) DOX: Doxorubicin 
 
  
Entry Delivery system 
Primary 
targeting 
Secondary 
 Targeting(a) 
Cytotoxic 
loaded(b) Cellular line Ref. 
1 MSNs 
RGD peptide 
(αvβ3Integrin, 
vascular) 
TAT peptide 
(Nuclear) 
DOX HeLa (Breast) [26] 
2 MSNs 
Folic acid 
(Membrane) 
DEX 
(Glucocorticoid/Nuclear) 
DOX 
HeLa (Folic +) 
HEK293 (Folic -) 
(Breast) 
[34] 
3 Hollow MSNs 
t-Lip-1 (Neurophilin) 
(Membrane + Nuclear) 
DOX 
MDA-MB-231 
(Breast) 
[38] 
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Table 2. MSNs models employed for dual therapeutic actions based on gene silencing. 
Entry Delivery system siRNA 
Tumor 
targeting 
Cytotoxic 
loaded(a) Cellular line Ref. 
1 MSNs 
Bcl-2  
Apoptosis blocker 
(Non-pump resistance) 
None DOX A2780/AD (Ovarian) [47] 
2 
Hollow 
MSNs 
Bcl-2  
Apoptosis blocker 
(Non-pump resistance) 
Folic acid DOX 
HeLa (Folic +) 
MCF-7 (Folic-) 
(Breast) 
[48] 
3 MSNs 
p-Glycoprotein (Pgp) 
(Pump resistance) 
None DOX 
KB-31 (DOX 
sensitive) 
KB-V1 (DOX 
resistant) 
[49] 
4 MSNs 
Several siRNA 
(Pump: Pgp, MRP1, 
ABCG2 
Non-pump: Bcl-2, 
cMYC, PXR) 
None DOX MCF-7 (Breast) [50] 
5 MSNs Anti-miR221 None TMZ 
C6 (TMZ 
sensitive),  
T98G (TMZ 
resistant) 
(Glioma) 
[51] 
6 MSNs VEGF-siRNA TAT peptide (Nuclear) DOX 
QGY-7703 
(Hepatic) [52] 
7 Magnetic MSNs 
Vasohibin-2 
(VEGF-siRNA) 
KALA peptide 
(Fusogenic) 
None SKOV3 (Ovarian) [53] 
 (a) DOX: Doxorubicin; TMZ: Temozolomide 
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Table 3. Multiple cytotoxic delivery from MSNs-based nanosystems. 
Entry Delivery system 
Drugs(s)  
Loaded(a) 
Drug 
location Release system 
Release 
stimuli Ref. 
 
1 MSNs 
DOX  grafted via 
hydrazone bond 
Pore and 
shell pH-dependent 
hydrazone cleavage pH decrease [59] 
CPT Pore 
2 MSNs 
RPM +  DOX 
PTX +  DOX 
Pore Pore DOX capping pH  decrease [60] 
 
3 MSNs 
CDDP Shell 
Polyelectrolyte pH 
sensitive shell pH decrease [61] 
RHD B Pore 
 
4 Hollow MSN 
CPT 
Pore 
Electrostatic 
assembly with 
quantum dots  
pH decrease [62] 
DOX 
 
5 MSNs 
PTX Shell 
Lipid shell None [63] 
GEM Pore 
       
6 MSNs 
Surfactant  
(PO4-3 based)  
Pore 
None 
pH 
dependent 
surfactant 
release 
[64] 
RVT Surfactant 
 
7 MSNs 
Surfactant 
(CTAB) Pore 
None 
pH 
dependent 
surfactant 
release 
[65] 
DOX Surfactant 
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(a) DOX: Doxorubicin; CPT: Camptothecin; RPM: Rapamycin; PTX: Paclitaxel; CDDP: Cisplatin; RHD 
B: Rhrodamine B; GEM: Gemcitabine; RVT: Resveratrol; IRN: Irinotecan; TCP: Tocopherol; CA4: 
Combretastatin A4. 
 
  
8 MSNs 
Surfactant-Lipid 
Hybrid Shell 
Lipid shell 
pH 
dependent 
shell 
cleavage 
[67] 
IRN Pore 
 
9 MSNs 
TCP-PEG-
succinate Shell Lipid shell linked 
by disulfide bond 
Redox  
(shell) 
pH  decrease 
[68] 
DOX Pore 
 
10 MSNs 
DOX 
Pore None 
pH  decrease 
[69] 
CA4 None 
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Table 4. MSNs-based systems for combined photochemotherapy. 
Entry Delivery system 
Drug 
loaded(a) 
Induced 
apoptotic 
effect(b) 
Physical 
sensitizer 
Cellular 
line Ref. 
1 MSNs CPT PDT 
Porphyrin-SO3-  
(surface) 
hν= 630-80 nm 
MDA-MB-
231 
(Breast), 
Capan 1 
(Pancreas) 
and 
HCT116 
(Colon) 
[72] 
2 
MSNs 
(Nanorods) 
DOX PDT 
Chlorin e6 
(SiO2 matrix) 
hν= 660 nm 
4T1 
(Mouse, 
Breast) 
HeLa 
(Human, 
Breast) 
293T 
(Human, 
Kidney) 
[73] 
3 MSNs DOX PDT 
Zn-Porphyrin 
(Surface) 
HeLa 
(Breast) [74] 
4 MSNs CDDP PDT 
Phthalocyanine 
(Pore) 
hν= 570-690 nm 
HeLa 
(Breast) [75] 
5 MSNs DOX PDT 
NaYF4:Yb3+/Er3+ 
hν= 980 nm 
SKOV3 
(Ovarian) [78] 
6 AuNR@MSNs DOX PTT 
Au core 
hν= 808 nm 
A549 
(Lung) [79] 
7 Fe3O4@MSN-Au DOX PTT 
Au shell 
hν= 780 nm 
MCF-7 
(Breast) [80] 
8 C(Graphene)-MSNs DOX PTT 
Coated graphene 
hν= 808 nm 
U251 
(Glioma) [81] 
9 
PPY-PAA@ 
MSNs 
DOX PTT Polypyrrole “yolk” 
HepG-2 
(Liver) [82] 
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hν= 808 nm 
10 CuS@MSNs DOX PTT 
CuS core 
hν= 980 nm 
HeLa 
(Breast) [85] 
11 CuS@MSNs 
DOX 
CUR 
PTT 
CCT 
CuS core 
hν= 980 nm 
MCF-7 
(Breast) [87] 
12 
M2O3@MSN-
Au25-
PNIPAAm 
DOX PTT 
Au25(SR)18 
(Pore) 
hν= 980 nm 
A549 
(Lung) [88] 
13 Au@MSNs DOX PTT 
Au core 
hν= 808 nm 
HeLa 
(Breast) [89] 
14 Au-PAA-Janus-MSNs DOX PTT 
Au (Janus) 
hν= 808 nm 
HepG-2 
(Liver) [90] 
15 MSN@Au DTX PTT 
Au Shell 
hν= 808 nm 
B16-F10 
(Melanoma) [91] 
(a) CPT: Camptothecin; DOX: Doxorubicin; CDDP: Cisplatin; DTX: Docetaxel; CUR: Curcumin. 
(b) PDT: Photodynamic Therapy; PTT: Photothermal Therapy; CCT: Combined Chemotherapy. 
  
D
ow
nl
oa
de
d 
by
 [B
ibl
iot
ec
a U
niv
ers
ida
d C
om
plu
ten
se
 de
 M
ad
rid
], 
[R
afa
el 
Ca
sti
llo
] a
t 0
6:2
8 1
2 J
uly
 20
16
 
54 
 
Table 5. Non MSNs-based nanosystems designed up to date for combined therapy. 
Double Targeting approach 
Entry Delivery system Primary targeting 
Secondary 
targeting 
Therapeutic 
drug 
loaded(a) 
Cellular line Ref. 
1 Liposome 
c(RGDfC) peptide 
(αvβ3Integrin) 
CDAEWVDVS 
peptide 
(p-Selectin) 
None 
4T1, MDA-MB-
231 
(Breast) 
[114] 
2 Polymeric 
RGD peptide 
(αvβ3Integrin) 
Interleukin 13 
peptide 
(Glioma) 
Cou-6 
C6 
HUVEC 
[115] 
3 
Silica + 
Magnetic 
Beads 
HER2 Aptamer MUC1 Aptamer None 
MCF-7, T47D, 
BT-474 and SK-
BR-3 (Breast) 
[119] 
 
Interfering RNAs and cytotoxic co-delivery 
Entry Delivery system siRNA 
Tumor  
targeting 
Therapeutic 
drug loaded Cellular line Ref. 
4 Polymeric 
Bcl-2  
Apoptosis blocker 
Folic acid DOX MCF-7 (Breast) [123] 
5 Polymeric 
Bcl-2  
Apoptosis blocker 
Folic acid DOX MCF-7 (Breast) [124] 
6 Polymeric 
Hsp90 
Hest shock 
protein 
LPLTPLP 
peptide 
DTX A549 (Lung) [126] 
7 Polymeric 
Survivin 
Apoptosis blocker 
None 
DOX 
PTX 
- [127] 
 
Monoclonal antibodies and cytotoxic codelivery 
Entry Delivery system 
Monoclonal 
antibody 
Tumor 
 targeting 
Therapeutic 
drug loaded Cellular line Ref. 
8 Liposome 
Anti GD2 
(Sialoganglioside) 
NGR peptide 
(CD13, tumor 
vessel) 
DOX 
HTLA, SH-
SY5Y and NXS2 
(Neuroblastoma) 
OVCAR-3 
[116] 
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(a) COU-6: Coumarin 6; DOX: Doxorubicin; DTX: Docetaxel; PTX: Paclitaxel; OXA: Oxalilplatin; 
Lamotrigine (LMT, antiepileptic drug) 
  
(ovarian) 
Colo-996N 
(lung) 
9 Polymeric Trastuzumab Folic acid DOX 
MCF-7 and BT-
474 (Breast) 
[117] 
10 Polymeric Gemcitabine None OXA 
AsPc1, BxPc3 
(Pancreas) [118] 
 
Drug efflux pump substrate plus therapeutic drug codelivery 
Entry Delivery system 
Drug efflux 
substrate Drug role 
Therapeutic 
drug loaded Cellular line Ref. 
11 Polymeric 
Pluronic® 
P123/F127 
Pgp modulator  LMT 
Brain sections of 
SE48H rats  
[128] 
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Figure 1: Schematic way of action of different reported strategies to overcome MDR in 
cancer cells. i) Cellular-nuclear targeting; ii) Drug-siRNA co-delivery; iii) Drug co-
delivery. iv) Drug efflux pump modulation. 
 
 
 
 
Figure 2. Schematic representative strategies for photodynamic therapy (PDT) (left; v) 
and photothermal therapy (PTT) (right; vi). 
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